BMS/Pfizer’s Eliquis On Priority Review Path Toward March 2012 Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Priority review designation for the Factor Xa inhibitor suggests FDA sees it as a major treatment advance over Pradaxa and Xarelto in reducing the risk of stroke among atrial fibrillation patients.